Dr. Michael C. Chen

Internal Medicine | Hospital Medicine
1959 NE Pacific St., 
Seattle, WA 
 (1563.9 mi)
Accepting New Patients
Offers Telehealth
1959 NE Pacific St., 
Seattle, WA 
 (1563.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Michael Chen is a Hospital Medicine provider in Seattle, Washington. Dr. Chen is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Hospital Medicine
Licenses
Hospitalist in WA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Premera

Locations

1959 NE Pacific St., Seattle, WA 98195
Other Locations
930 Sw Abbey St, Newport, OR 97365

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

2 Total Publications

Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
Journal: The journals of gerontology. Series A, Biological sciences and medical sciences
Published: February 12, 2020
Similar Doctors
Expertise in
2
conditions
Dr. Corrie E. Mcdaniel
Hospital Medicine | Pediatrics
Expertise in
2
conditions
Dr. Corrie E. Mcdaniel
Hospital Medicine | Pediatrics
2800 Sand Point Way Ne, 
Seattle, WA 
 (1.3 mi)
708-684-5465
Languages Spoken:
English, Bengali, Filipino, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Corrie Mcdaniel is a Hospital Medicine specialist and a Pediatrics provider in Seattle, Washington. Dr. Mcdaniel is highly rated in 2 conditions, according to our data. Her top areas of expertise are Urinary Tract Infection in Children, Neonatal Abstinence Syndrome, Jaundice, and Newborn Jaundice. Dr. Mcdaniel is currently accepting new patients.

Expertise in
1
conditions
Dr. Meghan M. Kiefer
Hospital Medicine
Expertise in
1
conditions
Dr. Meghan M. Kiefer
Hospital Medicine

The Association Of University Physicians

325 9th Ave, 
Seattle, WA 
 (3.2 mi)
206-731-3000
Experience:
16+ years
Languages Spoken:
English, Castilian, Korean, Mandarin, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Meghan Kiefer is a Hospital Medicine provider in Seattle, Washington. Dr. Kiefer has been practicing medicine for over 16 years is highly rated in 1 condition, according to our data. Her top area of expertise is End-Stage Renal Disease (ESRD). Dr. Kiefer is currently accepting new patients.

Expertise in
1
conditions
Dr. Marta E. Gorczyca
Hospital Medicine
Expertise in
1
conditions
Dr. Marta E. Gorczyca
Hospital Medicine

Virginia Mason Medical Center

925 Seneca St, 
Seattle, WA 
 (2.9 mi)
206-223-6600
Experience:
14+ years
Languages Spoken:
English, German, Greek, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Marta Gorczyca is a Hospital Medicine provider in Seattle, Washington. Dr. Gorczyca has been practicing medicine for over 14 years is highly rated in 1 condition, according to our data. Her top area of expertise is End-Stage Renal Disease (ESRD). Dr. Gorczyca is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition

We do not have enough information to identify the Areas of Expertise for this provider.

Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile